Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Priority and Status of Claims
1. This application is a CON of 16919677 07/02/2022, which claims benefit of the provisional application: 62870413 07/03/2019
2. Applicant’s remarks filed on 6/19/2026 are acknowledged. Claims 13-20 are pending in the application.
Responses to Amendments/Arguments
3. Applicant's arguments regarding the rejection of claims 13 and 16-17 under 35 U.S.C. 103 (a) over Phase II trial for antiviral activity for treating HIV-1 virus using Rilpivirine have been fully considered and they are persuasive. Therefore the rejection of claims 13 and 16-17 under 35 U.S.C. 103 (a) over Phase II trial for antiviral activity for treating HIV-1 virus using Rilpivirine has been withdrawn herein.
4. Since a terminal disclaimer against Patankar et al. ‘198 and Crauwels et al. ‘759 has not ben filed to the Office, therefore the rejection of 13-17 under the obviousness-type double patenting over Patankar et al. ‘198 and Crauwels et al. ‘759 is maintained.
Applicants are requested to file a terminal disclaimer to overcome the rejection.
Claim Objections
5. Claim 18-20 are objected to as being dependent on rejected claim 13.
6. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to REI TSANG SHIAO whose telephone number is (571)272-0707. The examiner can normally be reached on 8:30 am-5:00 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/REI TSANG SHIAO/
Rei-tsang Shiao, Ph.D.Primary Examiner, Art Unit 1691
July 27, 2026
Prosecution Insights